Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

21.00 -3.87 (-15.56%)
Streaming Delayed Price Updated: 10:25 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Insights into Tango Therapeutics's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Unveiling 5 Analyst Insights On Tango Therapeutics ↗
 
Via Benzinga
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
The Analyst Landscape: 5 Takes On Tango Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Tango Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Analyst Expectations For Tango Therapeutics's Future ↗
 
Via Benzinga
News headline image
Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Forecasting The Future: 4 Analyst Projections For Tango Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Tango Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity ↗
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tango Therapeutics Announces Discontinuation of TNG348 Program
From Tango Therapeutics
Via Business Wire
News headline image
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗
TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
From Tango Therapeutics, Inc.
Via Business Wire
News headline image
Tango Therapeutics to Participate in Upcoming Investor Conferences
From Tango Therapeutics, Inc.
Via Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.